Momelotinib Shows Durability and Safety in Myelofibrosis at 48 Weeks
Aaron T. Gerds, MD, MS, discusses the 48-week results of the MOMENTUM trial of momelotinib, a JAK1/JAK2 inhibitor that is being investigated specifically for the treatment of anemic patients with myelofibrosis.
Closing Remarks on the Future Treatment Landscape of Myelofibrosis
Aaron Gerds, MD, MS, offers closing remarks on the outlook for the treatment of myelofibrosis, and shares advice for community oncologists.
Emerging Research in Myelofibrosis Treatment
A thorough review of promising therapies currently under investigation for the treatment of myelofibrosis.
Treatment Sequencing Considerations in Myelofibrosis
An expert oncologist overviews quality-of-life data and considerations in treatment sequencing in myelofibrosis.
Potential Role of Momelotinib in Myelofibrosis
Aaron Gerds, MD, MS, discusses the MOMENTUM study and the potential role of momelotinib in the myelofibrosis treatment landscape.
Approved Therapies for Myelofibrosis
A comprehensive overview of ruxolitinib, fedratinib, and pacritinib, the approved therapies for the treatment of myelofibrosis.
Myelofibrosis: Molecular Pathways and Prognostic Factors
An expert on hematologic malignancies discusses the prognostic factors and molecular pathways involved in myelofibrosis.
Overview of Myelofibrosis Types and Presentations
Aaron Gerds, MD, MS, explains the types, presentations, and classic symptoms of myelofibrosis.
MOMENTUM Aims to Complete Development of Momelotinib for Myelofibrosis Treatment
Aaron T. Gerds, MD, MS, discusses the clinical trial development of momelotinib, a JAK1/JAK2 inhibitor that is being investigated for the treatment of patients with myelofibrosis.
Luspatercept Lowers the Transfusion Burden in Patients With Myelofibrosis-Associated Anemia
Aaron Gerds, MD discusses the results of a phase II BELIEVE study of luspatercept as treatment of patients with myelofibrosis-associated anemia.
2 Clarke Drive Cranbury, NJ 08512